You know... I remember that question and at the time, I really didn't have an answer for you. A lot of this science is very very new to me. I intended to look into it so at least I could respond to you with something... but then, I forgot. :(
I know probably more than some of our non-science investors about DCVax therapies, but my knowledge of the other immunotherapies is far behind that (PD-1, PDL-1, CAR-Ts, and this t-Cell receptor therapies).
However, I just was looking more into KITE - as evidenced by my last post - and came across those very T cell receptors that KITE (and likely Gilead) intend to use to treat solid tumors. So I think I have more to learn from you and others about all of these other immunotherapies.
Perhaps what I'm sometimes decent at is getting a handle on what the particular science is and what it's expected to do, and then communicating that to other layman investors like myself. I think anyway. Flipper is even better at that... and he comes up with excellent analogies that can help us to better understand the science.
So I don't have an answer for you. I first have to understand better how TCRs work. And what exactly was it that you were wondering TCRs could overlap with? Direct or L? Or an overlapping repertoire of TCRs alone?
And can TCR's result in CRS and neurotoxities like CAR-Ts can?
Any insight you can give on TCRs is appreciated. I want to learn about them now because I think they may compete with DCVax-Direct. That's the kind of stuff that motivates (forces) me to learn about it - it's my mother instinct. Not my science instinct.
